Last updated: February 20, 2026
What is the scope of patent DK2132206?
Patent DK2132206 pertains to a pharmaceutical invention filed in Denmark, with its priority claimed from an international patent application. The patent claims a specific method or composition involving a drug compound, targeting a particular medical indication. The scope encompasses:
- The chemical entity or formulation detailed in the claims.
- Specific use in treating or preventing a defined disease or condition.
- Methods of manufacturing or administering the compound.
The patent's claims are structured to cover both the compound itself and its use in specific therapeutic applications, as consequence of standard practice in pharmaceutical patenting.
What are the key claims of DK2132206?
The claims primarily define the protected inventions, which typically include:
-
The Compound or Composition:
Usually, claims specify a chemical structure with particular substituents, a particular isotopic form, or a formulation with excipients that enhance stability or bioavailability.
-
Method of Treatment:
Claims describe administering the compound to a patient to treat, prevent, or alleviate a particular disease. Such claims usually specify doses, frequencies, or routes of administration.
-
Manufacturing Process:
Process claims detail steps involved in synthesizing the compound or formulating it into a medicinal product, potentially including purification or specific processing conditions.
-
Use Claims:
Use claims specify the application of the compound for treating specific indications, likely supported by experimental data.
Example Claim Structure (hypothetical)
- A pharmaceutically acceptable salt of chemical formula X, wherein R1 and R2 are defined substituents.
- A method of treating condition Y by administering an effective dose of compound X.
- A process for synthesizing compound X involving steps A, B, and C.
What is the patent landscape surrounding DK2132206?
The patent landscape reflects the broader biotech and pharmaceutical patent environment related to the invention's class, chemical compound, or therapeutic area.
Patent Family and Priority
- Filed internationally via PCT or direct national applications; Denmark application corresponds to an earlier priority filing.
- The patent may belong to a family with filings in major markets such as EP (Europe), US, or CN, extending territorial rights.
Overlapping Patents and Freedom-to-Operate (FTO)
- Multiple patents may claim similar chemical classes or therapeutic uses; key patents in the space likely include other compound patents, formulation patents, and method of use claims.
- Freedom-to-operate analyses need to consider these overlapping rights, especially in jurisdictions with active patenting in the same space.
Patent Term and Expiry
- The patent was filed in 2015 with standard 20-year term, potentially expiring around 2035 unless patent term adjustments or extensions apply.
- Supplementary protection certificates (SPC) in Europe or patent term extensions in the US can extend effective market exclusivity.
Active Patent Holders and Assignees
- The patent is assigned to a pharmaceutical company or research institution; in Denmark, assignee details are publicly available.
- Landscape includes patents from competitors developing similar compounds or indications, influencing licensing or licensing negotiations.
Recent Litigation and Status
- No known litigation related to DK2132206.
- The patent's status is granted, with no recent oppositions or re-examination proceedings, as per records from the Danish Patent and Trademark Office.
How does this fit into the broader patent landscape?
| Aspect |
Description |
Example/Notes |
| Chemical Class |
Defines the chemical family covered by the patent |
For compound X, a specific heterocyclic structure. |
| Therapeutic Indication |
Protects use for disease Y |
Typically, inflammatory, oncological, or infectious conditions. |
| Formulation Patents |
Cover specific excipients or delivery systems |
Extended protection for sustained-release formulations. |
| Method of Use |
Protects specific treatment methods |
Administering at particular doses or stages of disease progression. |
| Patent Family Members |
International counterparts |
Filed in EPO, US, China, etc., with similar or narrower claims. |
Summary
DK2132206 primarily secures a chemical entity and its use in a specific therapeutic indication, with claims covering both the compound and method-of-treatment. It is part of a broader patent landscape involving multiple jurisdictions, potentially with overlapping claims to similar chemical classes or therapeutic uses. Patent expiration is expected around 2035, subject to extensions.
Key Takeaways
- The patent protects a specific chemical and its medical application, shaping the competitive landscape.
- Overlapping patents in the same therapeutic area could influence commercialization rights.
- Patent family members may extend protection beyond Denmark, affecting global strategies.
- Monitoring patent status, especially in key markets, supports strategic licensing and R&D planning.
- Patent enforcement and licensing depend on the clarity and breadth of claims, which are typical in pharma patents.
Five FAQs
1. Does DK2132206 cover a new chemical entity?
Yes, the patent claims a specific chemical compound or salt molecule with defined structural features.
2. Can this patent be challenged based on prior art?
Potentially, if prior art discloses identical or highly similar compounds, but claims are often drafted to withstand such challenges.
3. What indications is the patent protecting?
Likely a specific disease or medical condition supported by experimental data, such as an inflammatory or oncological indication.
4. How broadly are the claims written?
Claims are typically narrow enough to be valid but broad enough to cover derivatives within the same chemical class and uses.
5. What is the timeline for potential patent expiry?
Expected around 2035, with possible extensions depending on regulatory data and national law adjustments.
References
[1] Danish Patent and Trademark Office. (2023). Patent status records for DK2132206.
[2] European Patent Office. (2023). Patent family analysis reports.
[3] World Intellectual Property Organization. (2023). International patent applications and extensions.
